Cargando…
Correction to: Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348614/ https://www.ncbi.nlm.nih.gov/pubmed/30691468 http://dx.doi.org/10.1186/s12931-019-0985-2 |
| _version_ | 1783390128798957568 |
|---|---|
| author | Driessen, M. T. Whalen, J. Buguth, B. Seewoodharry Vallejo-Aparicio, L. A. Naya, I. P. Asukai, Y. Alcázar-Navarrete, B. Miravitlles, M. García-Río, F. Risebrough, N. A. |
| author_facet | Driessen, M. T. Whalen, J. Buguth, B. Seewoodharry Vallejo-Aparicio, L. A. Naya, I. P. Asukai, Y. Alcázar-Navarrete, B. Miravitlles, M. García-Río, F. Risebrough, N. A. |
| author_sort | Driessen, M. T. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-6348614 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2019 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-63486142019-01-31 Correction to: Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective Driessen, M. T. Whalen, J. Buguth, B. Seewoodharry Vallejo-Aparicio, L. A. Naya, I. P. Asukai, Y. Alcázar-Navarrete, B. Miravitlles, M. García-Río, F. Risebrough, N. A. Respir Res Correction BioMed Central 2019-01-28 2019 /pmc/articles/PMC6348614/ /pubmed/30691468 http://dx.doi.org/10.1186/s12931-019-0985-2 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Correction Driessen, M. T. Whalen, J. Buguth, B. Seewoodharry Vallejo-Aparicio, L. A. Naya, I. P. Asukai, Y. Alcázar-Navarrete, B. Miravitlles, M. García-Río, F. Risebrough, N. A. Correction to: Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective |
| title | Correction to: Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective |
| title_full | Correction to: Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective |
| title_fullStr | Correction to: Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective |
| title_full_unstemmed | Correction to: Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective |
| title_short | Correction to: Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective |
| title_sort | correction to: cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a spanish national healthcare system perspective |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348614/ https://www.ncbi.nlm.nih.gov/pubmed/30691468 http://dx.doi.org/10.1186/s12931-019-0985-2 |
| work_keys_str_mv | AT driessenmt correctiontocosteffectivenessanalysisofumeclidiniumbromidevilanterol62525mcgversustiotropiumolodaterol55mcginsymptomaticpatientswithchronicobstructivepulmonarydiseaseaspanishnationalhealthcaresystemperspective AT whalenj correctiontocosteffectivenessanalysisofumeclidiniumbromidevilanterol62525mcgversustiotropiumolodaterol55mcginsymptomaticpatientswithchronicobstructivepulmonarydiseaseaspanishnationalhealthcaresystemperspective AT buguthbseewoodharry correctiontocosteffectivenessanalysisofumeclidiniumbromidevilanterol62525mcgversustiotropiumolodaterol55mcginsymptomaticpatientswithchronicobstructivepulmonarydiseaseaspanishnationalhealthcaresystemperspective AT vallejoapariciola correctiontocosteffectivenessanalysisofumeclidiniumbromidevilanterol62525mcgversustiotropiumolodaterol55mcginsymptomaticpatientswithchronicobstructivepulmonarydiseaseaspanishnationalhealthcaresystemperspective AT nayaip correctiontocosteffectivenessanalysisofumeclidiniumbromidevilanterol62525mcgversustiotropiumolodaterol55mcginsymptomaticpatientswithchronicobstructivepulmonarydiseaseaspanishnationalhealthcaresystemperspective AT asukaiy correctiontocosteffectivenessanalysisofumeclidiniumbromidevilanterol62525mcgversustiotropiumolodaterol55mcginsymptomaticpatientswithchronicobstructivepulmonarydiseaseaspanishnationalhealthcaresystemperspective AT alcazarnavarreteb correctiontocosteffectivenessanalysisofumeclidiniumbromidevilanterol62525mcgversustiotropiumolodaterol55mcginsymptomaticpatientswithchronicobstructivepulmonarydiseaseaspanishnationalhealthcaresystemperspective AT miravitllesm correctiontocosteffectivenessanalysisofumeclidiniumbromidevilanterol62525mcgversustiotropiumolodaterol55mcginsymptomaticpatientswithchronicobstructivepulmonarydiseaseaspanishnationalhealthcaresystemperspective AT garciariof correctiontocosteffectivenessanalysisofumeclidiniumbromidevilanterol62525mcgversustiotropiumolodaterol55mcginsymptomaticpatientswithchronicobstructivepulmonarydiseaseaspanishnationalhealthcaresystemperspective AT risebroughna correctiontocosteffectivenessanalysisofumeclidiniumbromidevilanterol62525mcgversustiotropiumolodaterol55mcginsymptomaticpatientswithchronicobstructivepulmonarydiseaseaspanishnationalhealthcaresystemperspective |